ClinicalTrials.gg
CompletedNCT03015259Updated Aug 24, 2022Results posted

Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients

A Phase 3 interventional study of Budesonide/Formoterol fumarate dihydrate and Symbicort in Asthma, sponsored by Kindeva Drug Delivery. Completed at 95 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-24.

Sponsored by Kindeva Drug Delivery · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,762
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
8th of 108
1,762 · median 124
Started
2016
with 5 others
Phase 3
51 of 110
3 open now
Registered
90th of 110
by date

Among the 110 studies testing budesonide in Asthma, this one is the 8th largest by enrollment of the 108 interventional ones that give a count, is one of 6 that started in 2016, is one of 51 in phase 3, and was the 90th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

A randomized multiple-dose, placebo-controlled, parallel group design consisting of a 2-week run-in period followed by a 6-week treatment period of the placebo, Test product (Budesonide 80 mcg / Formoterol fumarate dihydrate 4.5 mcg), or Reference product Symbicort® inhalation aerosol.

Read the detailed description

This is a pivotal trial that will examine therapeutic equivalence of a new generic fixed-dose combination product containing Budesonide 80 mcg / Formoterol fumarate dihydrate 4.5 mcg and reference listed drug (RLD) Symbicort® inhalation aerosol in adult patients with chronic but stable asthma as defined in National Asthma Education and Prevention Program Expert Panel Report 3 (NAEPP 3) guidelines. To ensure adequate study sensitivity the test and reference products should both be statistically superior to placebo (p\<0.05) with regard to the bioequivalent study primary endpoints.

A secondary study objective is the safety and tolerability of the test compound.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • bioequivalence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male or female subjects of non-childbearing or of committed to consistent and correct use of an acceptable method of
  • Diagnosed with asthma, as defined by the National Asthma Education and Prevention Program (NAEPP),at least 6 months prior to screening
  • Moderate-to-severe asthma with a pre-bronchodilator of >45% and \<85% of predicted normal, measured at least 6 hours after short-acting β agonist (SABA)and at least 24 hours after the last dose of long-acting β agonist (LABA), at the screening visit and on the day of treatment
  • >15% and >0.20 L reversibility of FEV1 within 30 minutes following 360 mcg of albuterol inhalation (pMDI)
  • Patients should be stable on their chronic asthma treatment regimen for at least 4 weeks prior to enrollment
  • Currently non-smoking; having not used tobacco products (i.e., cigarettes, cigars, pipe tobacco) within the past year, and having \< 10 pack-years of historical use
  • Able to replace current regularly scheduled short-acting β agonists (SABAs) with salbutamol/albuterol inhaler for use only on an as-needed basis for the duration of the study (subjects should be able to withhold all inhaled SABAs for at least 6 hours prior to lung function assessments on study visits)
  • Willing to discontinue their asthma medications (inhaled and long-acting β agonists) during the run-in period and for the remainder of the study
  • Willingness to give their written to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Life-threatening asthma, defined as a history of asthma episodes(s) requiring intubation, and/or associated with hypercapnia, respiratory arrest or hypoxic seizures, asthma-related syncopal episodes(s), or hospitalizations within the past year or during the run-in period
  • Significant respiratory disease other than asthma ( (COPD), interstitial lung disease, etc.)
  • Evidence or history of disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that, in the opinion of the investigator, would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbated during the study
  • Patients who required systemic (for any reason) within the past 4 weeks
  • to any sympathomimetic drug (e.g., formoterol or albuterol) or any inhaled, intranasal, or systemic corticosteroid therapy
  • Patients currently receiving β-blockers
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1,762 participants (actual)

Study arms

  • Experimental
    Treatment 1

    Generic Budesonide/Formoterol Fumarate Dihydrate (80mcg/4.5mcg) Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period

    Drug: Budesonide/Formoterol fumarate dihydrate

  • Active comparator
    Treatment 2

    Symbicort (Budesonide/Formoterol Fumarate Dihydrate) Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period

    Drug: Symbicort

  • Placebo comparator
    Treatment 3

    Placebo Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period

    Drug: Placebo

Interventions

  • DrugBudesonide/Formoterol fumarate dihydrate

    Drug pages: Budesonide · Formoterol

    Experimental: Treatment 1

    Also known as: Generic Budesonide/Formoterol fumarate dihydrate

  • DrugSymbicort

    Active Comparator: Treatment 2

    Also known as: Budesonide/Formoterol fumarate dihydrate

  • DrugPlacebo

    Placebo Comparator: Treatment 3

06

What researchers measure

Primary outcomes

  1. Area Under the Serial Forced Expiratory Volume in 1 Second (FEV1)

    FEV1 Area calculated over 12 hours (measurements at 0, 1, 2, 3, 4, 6, 8, 12 hours post-dose) on Day 1 of treatment. Because this was a primary endpoint, Per Protocol Population used to calculate this endpoint.

    Time frame: Day 1

  2. Change From Baseline in FEV1 Measured in the Morning at the End of Treatment Visit

    Average predose FEV1 at End of Treatment defined as the average of all predose assessments on Day 42 (+/- 7 days). Baseline was defined as the average of 2 predose FEV1 values obtained on Day 1. The endpoint of baseline-adjusted predose FEV1 at end of treatment was calculated as follows: \[FEV1 at end of treatment\] - \[Baseline FEV1\].

    Time frame: Day 1 - Day 49

Secondary outcomes

  1. Number of Participants With Adverse Events

    Number of participants reporting at least one adverse event (safety population)

    Time frame: 6 Weeks

07

Results

Posted Aug 24, 2022
Limitations and caveats
There were no limitations to the trial protocol, no early termination or technical problems.

Participant flow

Participant flow — Overall Study
MilestoneTreatment 1Treatment 2Treatment 3
Started613622204
Completed598604199
Not completed15185

Outcome measures

PrimaryArea Under the Serial Forced Expiratory Volume in 1 Second (FEV1)

FEV1 Area calculated over 12 hours (measurements at 0, 1, 2, 3, 4, 6, 8, 12 hours post-dose) on Day 1 of treatment. Because this was a primary endpoint, Per Protocol Population used to calculate this endpoint.

Time frame:
Day 1
Reported as:
Least squares mean · l * hr
Area Under the Serial Forced Expiratory Volume in 1 Second (FEV1)
l * hrTreatment 1Treatment 2Treatment 3
Area Under the Serial Forced Expiratory Volume in 1 Second (FEV1)4.4453 ± 0.15524.2790 ± 0.15471.6876 ± 0.2782
Statistical analysis
  • Treatment 1 vs Treatment 2 vs Treatment 3 · Test/referece ls mean ratio: 1.040 · 90% CI 0.958 to 1.130Fieller's formula was applied
PrimaryChange From Baseline in FEV1 Measured in the Morning at the End of Treatment Visit

Average predose FEV1 at End of Treatment defined as the average of all predose assessments on Day 42 (+/- 7 days). Baseline was defined as the average of 2 predose FEV1 values obtained on Day 1. The endpoint of baseline-adjusted predose FEV1 at end of treatment was calculated as follows: \[FEV1 at end of treatment\] - \[Baseline FEV1\].

Time frame:
Day 1 - Day 49
Reported as:
Least squares mean · liter
Change From Baseline in FEV1 Measured in the Morning at the End of Treatment Visit
literTreatment 1Treatment 2Treatment 3
Change From Baseline in FEV1 Measured in the Morning at the End of Treatment Visit0.3096 ± 0.01620.3077 ± 0.01620.1236 ± 0.0285
Statistical analysis
  • Treatment 1 vs Treatment 2 vs Treatment 3 · Test/reference ls mean ratio: 1.004 · 90% CI 0.889 to 1.140Fieller's formula was applied
SecondaryNumber of Participants With Adverse Events

Number of participants reporting at least one adverse event (safety population)

Time frame:
6 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsTreatment 1Treatment 2Treatment 3
Upper respiratory tract infection12157
Nasopharyngitis7114
Viral upper respiratory tract infection641
Bronchitis342
Asthma172439
Cough443
Headache482
Chest discomfort102
Statistical analysis
  • Treatment 1 vs Treatment 2 vs Treatment 3 ·

Adverse events

Collected over Day 1 - Day 70. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment 10/613 (0%)4/613 (0.7%)121/613 (19.7%)
Treatment 20/622 (0%)3/622 (0.5%)138/622 (22.2%)
Treatment 30/204 (0%)2/204 (1%)71/204 (34.8%)
Most frequent serious events
Most frequent serious events
EventTreatment 1Treatment 2Treatment 3
Abdominal painGastrointestinal disorders0/6130/6221/204
AsthmaRespiratory, thoracic and mediastinal disorders0/6130/6221/204
cerebrospinal fluid leakageNervous system disorders1/6130/6220/204
staphylococcal skin infectionInfections and infestations1/6130/6220/204
Alcoholic pancreatitisGastrointestinal disorders1/6130/6220/204
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/6130/6220/204
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/6131/6220/204
MyositisMusculoskeletal and connective tissue disorders0/6131/6220/204
Head injurtInjury, poisoning and procedural complications0/6131/6220/204
Most frequent other events
Showing 10 of 26
Most frequent other events
EventTreatment 1Treatment 2Treatment 3
respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders35/61348/62248/204
asthmaRespiratory, thoracic and mediastinal disorders17/61324/62239/204
infections and infestationsInfections and infestations54/61358/62220/204
upper respiratory tract infectionInfections and infestations12/61315/6227/204
nasopharyngitisInfections and infestations7/61311/6224/204
gastrointestinal disordersGastrointestinal disorders11/61312/6222/204
injury, poisoning and procedural complicationsInjury, poisoning and procedural complications8/61311/6222/204
nervous system disordersNervous system disorders9/61310/6222/204
musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders8/61310/6222/204
coughRespiratory, thoracic and mediastinal disorders4/6134/6223/204

Baseline characteristics

Randomized participants who received at least 1 dose of study drug during Treatment Period

Age, Continuous
Age, Continuous(years)Treatment 1Treatment 2Treatment 3Total
Mean46.3 ± 15.0245.5 ± 14.4445.5 ± 14.7845.8 ± 14.73
Sex: Female, Male
Sex: Female, Male(Participants)Treatment 1Treatment 2Treatment 3Total
Female375392137904
Male23823067535
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment 1Treatment 2Treatment 3Total
Hispanic or Latino15315155359
Not Hispanic or Latino4604711491080
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment 1Treatment 2Treatment 3Total
American Indian or Alaska Native2002
Asian56415
Native Hawaiian or Other Pacific Islander0000
Black or African American10711243262
White4904951541139
More than one race0000
Unknown or Not Reported99321
Body Mass Index
Body Mass Index(kg/m^2)Treatment 1Treatment 2Treatment 3Total
Mean30.73 ± 7.66731.27 ± 8.10830.93 ± 7.96030.99 ± 7.900
08

Study locations

95 sites
  • Clinical Research Center of Alabama LLC
    Birmingham, Alabama 35209, United States
  • Elite Clinical Studies
    Phoenix, Arizona 85018, United States
  • Clinical Research Consortuim Arizona
    Tempe, Arizona 85253, United States
  • Little Rock Allergy and Asthma Clinical Research Center
    Little Rock, Arkansas 72205, United States
  • Anaheim Clinical Trials LLC
    Anaheim, California 92801, United States
  • Warren W Pleskow MD
    Encinitas, California 98104, United States
  • Allergy and Asthma Specialists Medical Group
    Huntington Beach, California 92647, United States
  • California Allergy and Asthma Medical Group Inc
    Los Angeles, California 90025, United States
  • Jonathan Corren MD, Inc.
    Los Angeles, California 90025, United States
  • Southern California Institute For Respiratory Diseases, Inc.
    Los Angeles, California 90048, United States
  • Allergy and Asthma Associates of Southern California, A Medical Group, Inc.
    Mission Viejo, California 92691, United States
  • Integrated Research Group Inc
    Riverside, California 92506, United States
  • Allied Clinical Research LLC
    Sacramento, California 95842, United States
  • Allergy and Asthma Associates of Northern California
    San Jose, California 95117, United States
  • Allergy & Asthma Clinical Research
    Walnut Creek, California 94598, United States
  • Allainz Research Institute Inc
    Westminster, California 92683, United States
  • Western States Clinical Research Inc
    Arvada, Colorado 80401, United States
  • Colorado Allergy and Asthma Centers PC
    Centennial, Colorado 80112, United States
  • IMMUNOe Research Centers
    Centennial, Colorado 80112, United States
  • Asthma and Allergy Associates PC
    Colorado Springs, Colorado 80907, United States
  • Colorado Allergy and Asthma Centers PC
    Denver, Colorado 80230, United States
  • Innovative Clinical Research Inc
    Lafayette, Colorado 80026, United States
  • Rocky Mountain Center for Clinical Research
    Wheat Ridge, Colorado 80033, United States
  • Saint Francis Sleep Allergy and Lung Institute
    Clearwater, Florida 33765, United States
  • Southeastern Integrated Medical
    Gainesville, Florida 32607, United States
  • Innovative Research of West Florida
    Largo, Florida 33756, United States
  • San Marcus Research Clinic Inc
    Miami, Florida 33015, United States
  • Prestige Clinical Research Center Inc
    Miami, Florida 33133, United States
  • Clintex Research Group, Inc
    Miami, Florida 33135, United States
  • Suncoast Research Group LLC
    Miami, Florida 33135, United States
  • Applemed Research Inc
    Miami, Florida 33155, United States
  • Biotech Pharmaceutical Group, LLC
    Miami, Florida 33155, United States
  • Research Institute of South Florida Inc
    Miami, Florida 33173, United States
  • Advanced Research Institute Inc
    New Port Richey, Florida 34653, United States
  • Emerald Coast Research Associates
    Panama City, Florida 32405, United States
  • Allergy and Asthma Dtc
    Tallahassee, Florida 32308, United States
  • Asthma and Allergy Center of Chicago Sc
    River Forest, Illinois 60305, United States
  • Analab Clinical Research Inc
    Lenexa, Kansas 66219, United States
  • Paul Shapero's Private Practice
    Bangor, Maine 04401, United States
  • Chesapeake Clinical Research Inc
    Baltimore, Maryland 212236, United States
  • Bethesda Allergy Asthma and Research Center LLC
    Bethesda, Maryland 20814, United States
  • Genesis Clinical Research and Consulting LLC
    Fall River, Massachusetts 02723, United States
  • Infinity Medical Research LLC
    North Dartmouth, Massachusetts 02747, United States
  • Northeast Medical Research Associates Inc
    North Dartmouth, Massachusetts 02747, United States
  • Clinical Research Institute, Inc.
    Minneapolis, Minnesota 55402, United States
  • Clinical Research of the Ozarks INC
    Columbia, Missouri 65203, United States
  • Clinical Research of the Ozarks Inc
    Rolla, Missouri 65401, United States
  • Midwest Clinical Research LLC
    Saint Louis, Missouri 63141, United States
  • The Clinical Research Center LLC
    Saint Louis, Missouri 63141, United States
  • Montana Medical Research
    Missoula, Montana 59808, United States
  • Pioneer Clinical Research LLC
    Bellevue, Nebraska 68005, United States
  • The Asthma and Allergy Center PC
    Bellevue, Nebraska 68123, United States
  • Clinical Research Consortium Nevada
    Las Vegas, Nevada 89102, United States
  • Allied Clinical Research LLC
    Reno, Nevada 89523, United States
  • Ocean Allergy & Respiratory Research Center
    Brick, New Jersey 08724, United States
  • Atlantic Research Center LLC
    Ocean Township, New Jersey 07712, United States
  • Princeton Center For Clinical Research
    Skillman, New Jersey 08558, United States
  • Allergy Partners of Western North Carolina
    Asheville, North Carolina 28801, United States
  • Rapha Institute for Clinical Research
    Fayetteville, North Carolina 28314, United States
  • North Carolina Clinical Research
    Raleigh, North Carolina 27607, United States
  • Empirical Medical Research
    Canton, Ohio 44718, United States
  • Bernstein Clinical Research Center Inc
    Cincinnati, Ohio 45231, United States
  • New Horizons Clinical Research
    Cincinnati, Ohio 45242, United States
  • Toledo Center For Clinical Research
    Sylvania, Ohio 43560, United States
  • Toledo Institute of Clinical Research
    Toledo, Ohio 93617, United States
  • OK Clinical Research, LLC
    Edmond, Oklahoma 73034, United States
  • Oklahoma Institute of Allergy and Asthma Clinical Research LLC
    Edmond, Oklahoma 73131, United States
  • Santiago Reyes, MD
    Oklahoma City, Oklahoma 73112, United States
  • Vital Prospects Clinical Research Institute PC
    Tulsa, Oklahoma 74136, United States
  • Allergy and Asthma Research Group
    Eugene, Oregon 97401, United States
  • Clinical Research Institute of Southern Oregon PC
    Medford, Oregon 97504, United States
  • Allergy Associates Research Center LLC
    Portland, Oregon 97202, United States
  • Clinical Trial Center LLC
    Jenkintown, Pennsylvania 19046, United States
  • Montgomery Medical Inc
    Smithfield, Pennsylvania 15478, United States
  • Asthma & Allergy Physicians of Rhode Island Clinical Research Institute
    Warwick, Rhode Island 02886, United States
  • ADAC Research
    Greenville, South Carolina 29607, United States
  • National Allergy and Asthma Research, LLC
    North Charleston, South Carolina 29420, United States
  • S. Carolina Pharmaceutical Research
    Spartanburg, South Carolina 29303, United States
  • Spartanburg Medical Research
    Spartanburg, South Carolina 29303, United States
  • New Phase Research & Development
    Knoxville, Tennessee 37909, United States
  • AARA Research Center
    Dallas, Texas 75231, United States
  • Pharmaceutical Research & Consulting Inc
    Dallas, Texas 75231, United States
  • Western Sky Medical Research
    El Paso, Texas 79903, United States
  • Pioneer Research Solutions
    Houston, Texas 77099, United States
  • Metroplex Pulmonology & Sleep Center
    McKinney, Texas 75069, United States
  • Central Texas Health Research Corporation
    New Braunfels, Texas 78130, United States
  • Quality Assurance Research Center
    San Antonio, Texas 78207, United States
  • Allergy and Asthma Research Center PA
    San Antonio, Texas 78229, United States
  • Sylvana Research Associates
    San Antonio, Texas 78229, United States
  • Allergy Asthma Research Institute
    Waco, Texas 76712, United States
  • National Clinical Resources Inc
    Provo, Utah 84604, United States
  • Timber Lane Allergy and Asthma Research LLC
    South Burlington, Vermont 05403, United States
  • Clinical Research Partners LLC
    Henrico, Virginia 23233, United States
  • Marycliff Allergy Specialists PS
    Spokane, Washington 99202, United States
  • Allergy Asthma and Sinus Center
    Greenfield, Wisconsin 53228, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Feb 2018, 13 months.

Results were first posted in Aug 2022, 4 years 6 months after primary completion. A results delay was requested in Dec 2018.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 13 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2017
First posted
Jan 10, 2017
StartActual
Dec 29, 2016
Primary completionActual
Feb 8, 2018
CompletionActual
Feb 8, 2018
Results delay requested
Dec 13, 2018
Results first posted
Aug 24, 2022
Last update
Aug 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03015259
Lead sponsor
Kindeva Drug Delivery
Responsible party
Sponsor
First posted
Jan 10, 2017
Start date
Dec 29, 2016
Primary completion
Feb 8, 2018
Completion
Feb 8, 2018
Results posted
Aug 24, 2022
Last update
Aug 24, 2022

Study contacts

KINDEVA I DD, PhD
study chair · Kindeva Drug Delivery

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Formoterol

Start the discussion